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iabetes, and particularly type 2 diabetes, is one
of the most signiﬁcant public health problems
facing Western civilization. Every day, 4,100
people in the U.S. are diagnosed with diabetes.
Of those with diabetes, each day, 230 have their legs
amputated, 120 are newly placed on kidney dialysis, and 55
become blind. Overall, in the U.S., almost 7% of the entire
population (21 million people) have diabetes, including
1 in 5 individuals over the age of 60 years. Diabetes is the
sixth leading cause of death (and is likely underreported),
and people with diabetes have twice the risk of death as
someone of the same age without diabetes. The primary
cause of death in individuals with diabetes is not from
diabetes itself but from the complications of the disease.
In all, the cost of diabetes to the U.S. economy is thought
to be nearly 132 billion USD in lost productivity and in
direct medical care costs (1). To predict those at risk of
diabetes, design efﬁcacious behavioral and clinical inter-
ventions, and identify critical targets for pharmacologic
therapy, a better understanding of the pathways and
mechanisms leading to diabetes is required. It is this need
for a more complete understanding of etiology that leads
to the fundamental importance of genetic studies.
There is extensive and consistent evidence that genetic
factors play an important role in modifying an individual’s
risk for type 2 diabetes (2–6). A major research focus for
several decades has been the identiﬁcation of genes con-
tributing to diabetes risk. Unlike the many forms of
maturity-onset diabetes in the young (MODY) that are
transmitted as a single gene defect and appear “Mende-
lian” in nature (7), typical type 2 diabetes is multifactorial
in its transmission (8). Unlike type 1 diabetes, which is
multifactorial but has major genetic contribution by genes
in the human major histocompatibility complex (MHC)
(including the HLA and other genes [9]), type 2 diabetes
genetic risk has few genes of major effect (10). Thus, the
search for genes contributing to risk of type 2 diabetes has
been difﬁcult, and the genes themselves have been elusive.
The methods for gene discovery for complex human
diseases such as type 2 diabetes have been rapidly evolv-
ing. Previous research was focused on evaluation of
families with multiple cases of diabetes to detect linkage
to a gene in a hypothetical causal pathway or testing
functional variants in candidate genes using a case-control
approach (11,12). Historically, these studies were limited
by both a small population size that reduced statistical
power to detect all but major gene effects and low genomic
coverage, where only a few variants within the candidate
gene are tested. A problem of these earlier studies was that
the positive ﬁndings were not often replicated, thereby
generating confusion and concern for the application of
genetic methods to diabetes risk assessment. With the
advent of the International HapMap Project (13,14), the
limitation of genomic coverage was effectively resolved.
Reagents are now available to cover the human genome at
a 5-kb resolution, and the structure of the individual
candidate genes can now be characterized, making popu-
lation size (and replication of novel ﬁndings) the primary
requirement for gene discovery.
Recently, a series of genome-wide association scans for
type 2 diabetes were published (15–25). These scans have
taken the approach of an unbiased (agnostic) view of the
genome related to type 2 diabetes genetic risk. Hundreds
of thousands of single-nucleotide polymorphisms (SNPs)
across the genome have been assayed in samples from
populations of almost exclusively northern European an-
cestry, and novel genes (TCF7L2, SLC30A8, IDE-KIF11-
HHEX, CDKAL1, CDKN2A-CDKN2B, IGF2BP2, FTO, etc.
[26]) with uncertain function pertaining to risk of type 2
diabetes have been identiﬁed. Despite the increase in the
number of genes from the few (PPARG, KCNJ11,
CAPN10) to the many (now over a dozen), the contribu-
tion of these genes to both the overall and the genetic risk
remains small (27). Hence, there are likely many more
genes to be identiﬁed, any one of which could identify a
key pathway involved in disease.
The article in this issue of Diabetes by Gaulton et al. (28)
presents a variation on the candidate gene approach in the
whole genome era. Using the framework of FUSION
(Finland-U.S. Investigation of Type 2 Diabetes Genetics)
that was applied to the genome-wide association scans,
the investigators have characterized a battery of 222
candidate genes associated with type 2 diabetes risk.
Unrelated individuals were abstracted from the FUSION
families, and these 1,161 case subjects with type 2 diabetes
and 1,174 normoglycemic control subjects were assayed
for 3,531 SNPs in the candidate genes. The candidate
genes were selected using a number of strategies, includ-
ing use of bioinformatics and text/vocabulary processing,
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genome can be considered a candidate-wide association
scan (CWAS). Using additional HapMap data, the investi-
gators were able to increase the number of SNPs used in
the analyses by imputing genotypes of 7,500 additional
SNPs within/near the candidate genes, thereby capturing
nearly all of the variants in the candidates. Using this
CWAS approach, the FUSION team replicated associations
between numerous genes with type 2 diabetes risk and
identiﬁed two additional genes (RAPGEF1 and TP53)
worthy of further study. The authors suggest that
RAPGEF1 represents a strong candidate because of its
role in insulin signaling. In addition, the RAPGEF1 path-
way may be involved in regulation of proglucagon gene
expression in intestinal endocrine L-cells (29), providing
another mechanism for its effect on risk of type 2 diabetes.
TP53, whereas primarily used as a target of breast cancer
prognosis (30), is proposed here to be an indicator of
apoptosis in the insulin-producing -cells of the pancreas.
This study demonstrates that not only are there likely
additional genes to be discovered that affect an individu-
al’s risk of diabetes, but there are multiple approaches
beyond genome-wide association scans alone that can be
used for gene discovery.
There are both strengths and weaknesses associated
with the contribution by Gaulton et al. (28). The strengths
include the two-stage CWAS approach that uses novel text
mining approaches to identify candidate genes and path-
ways that could be associated with risk of type 2 diabetes.
In addition, the sample size of 1,000 case subjects and
1,000 control subjects, while not particularly large in the
context of genome-wide coverage, has extensive genomic
coverage of the candidates in a homogeneous population.
Interestingly, this strength can also be viewed as a weak-
ness. The sample only contains Finns, so there is little
knowledge whether these same genes/pathways would be
observed in other ethnic groups. In addition, the large
battery of candidate genes and SNPs generates concern
over multiple testing of associations and power associated
with the study. This potential limitation can be addressed,
in part, by both conduct of additional studies in different
ethnic groups and by replication in other populations of
the same ethnicity. There is also an issue of confounding
by BMI so that it remains uncertain whether the genes
identiﬁed are related to diabetes risk, or obesity risk, or
after adjustment for BMI in the analytical models, any of
the signiﬁcant associations with diabetes becomes lost.
While candidate gene studies and coding region analyses
have the advantage of being “hypothesis-driven,” they are
also “hypothesis-limited”; not all novel pathways and mo-
lecular mechanisms can be identiﬁed and interrogated.
Finally, the question remains from ages past: can negative
results from the CWAS be ignored?
Within the context of studies with modest population
sizes, the thresholds for detecting signiﬁcance in the
literature are varied. In this study, the authors have used
different thresholds for “biologically relevant candidate
genes” (P  0.10) versus other standard statistical correc-
tions. Whereas this may protect against false-negative
results, it may also include more SNPs within candidate
genes for follow-up. Other aspects of the study that could
lead to false-negative results include the overall power
(low) for detection of associations, poor coverage of the
candidate genes (SNP selection), gene-gene and gene-
environment interaction (or correlation), or phenotype
deﬁnition.
The genetic risk factors for both type 1 and type 2
diabetes are being identiﬁed and the etiologic pathways
are being dissected. Currently, there are at least 10 genes
that appear to inﬂuence risk of type 1 diabetes (31) and 18
of type 2 diabetes (32), yet much needs to be done to
further understand how, in a pathophysiological sense,
variation in each of the genes modiﬁes risk, how we can
predict who is at risk, and how we can intervene to reduce
the risk to an individual. Three speciﬁc areas of future
research are easily identiﬁed. First, and as noted in the
current article, the pathway from gene to clinical outcome
(diabetes) goes through protein products that are “inter-
mediate”—quantitative phenotypes that are closer to the
functional defect. Examination of these diabetes-related
quantitative traits may provide important insight into the
disease risk transition from normal glucose tolerance to
type 2 diabetes. Second, resequencing of coding regions
can offer an efﬁcient way to focus the search for causal
variants. It is estimated that coding regions make up 1%
of the genome sequence, yet likely contain a much larger
fraction of all causal variants. Studies that are limited to
coding regions, however, will not identify regulatory vari-
ants that inﬂuence disease. Third, evolutionary conserva-
tion across relevant species can provide a means to
identify functional sites in the human genome. Evolution-
ary analysis of sequence data suggests that altering se-
quence in regulatory regions may be as deleterious as
altering sequence in coding regions. These future areas of
research will need to be integrated with the ongoing
epidemiologic studies that identify the important modiﬁ-
able risk factors that interact with the host genotype.
Using these current and future approaches to understand-
ing the human genome, the potential to modify the current,
almost inexorable, natural history of genetic risk, through
quantitative trait (intermediate phenotype) abnormalities
leading to clinical diabetes and its complications, is be-
coming more realistic. Understanding the pathophysiolog-
ical mechanisms that these genes identify should hopefully
lead to signiﬁcant advances in the next decade. Thus,
further identiﬁcation of genes for diabetes and its compli-
cations will provide better understanding of etiopathogen-
esis and clear delineation of targets for intervention.
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